Clindamycin phosphate/Fosmidomycin

克林霉素磷酸酯/膦胺霉素

Report date: 2022/07/04 19:38:02

Base Information

Drug NameClindamycin phosphate/Fosmidomycin
Drug Alias Name膦胺霉素/克林霉素磷酸酯Clindamycin/fosmidomycin膦胺霉素克林霉素磷酸酯Clindamycin phosphate and FosmidomycinFosmidomycin/clindamycin +[7] 
ClassificationSmall molecules
Mechanisms of Action50S ribosomal subunit inhibitorsOxidoreductases inhibitorsProtein biosynthesis inhibitors
Targets50S ribosomal subunitOxidoreductases
Therapy Area/IndicationsMalaria
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMozambique
CombinationsYes Clindamycin phosphateFosmidomycin
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesJomaa Pharma Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJomaa Pharma Gmbh
Active IndicationsN/A
Inactive IndicationsMalaria

Other Information

ATC CodeN/A
Related LinksN/A